ESAs and IV iron
in review
4 min read
Updated 2026-11-01
ESAs and IV iron in CKD
Iron first (thresholds by dialysis status), then an ESA if Hb stays low and symptoms or transfusion risk justify it. ESA preferred over HIF-PHI (KDIGO 2026, 2D). Keep Hb <115 g/L (1D). General iron-deficiency formulations and reactions → iron deficiency.
mechanism
ESAs: recombinant erythropoietin or analogues. HIF-PHIs: oral; stabilise HIF → endogenous EPO and better iron handling.
dosing
iron — KDIGO 2026
| non-dialysis / PD | haemodialysis | |
|---|---|---|
| start if | ferritin <100 + TSAT <40%, or ferritin 100–300 + TSAT <25% | ferritin ≤500 + TSAT ≤30% |
| route | oral or IV (preference, severity, cost) | IV, proactive (PIVOTAL (2019)) |
| hold if | ferritin >700 or TSAT ≥40% | same |
| monitor | Hb, ferritin, TSAT every 3 months | every 1–3 months |
| IV iron | max single dose | CKD notes |
|---|---|---|
| iron sucrose | 200 mg (non-dialysis), 400 mg (PD) | 1 g needs 5 × 200 mg over 5 weeks |
| ferric derisomaltose | 1000 mg or 20 mg/kg | full dose in one sitting |
| ferric carboxymaltose | 750 mg (FDA) / 1000 mg (EMA) | hypophosphataemia, especially early CKD and transplant |
| ferric gluconate | 125 mg | weekly doses |
| ferumoxytol | 510 mg | single sitting |
- Switch oral → IV after 1–3 months of poor response or intolerance
- No routine test dose or steroid/antihistamine premedication; give only where hypersensitivity can be managed
- Hold during systemic infection
- Ferric citrate used as a phosphate binder raises iron indices → count it in iron decisions (KDOQI)
- Profound iron deficiency without anaemia (ferritin <30 + TSAT <20%), especially with heart failure → consider treating (KDIGO, KDOQI) → iron deficiency
ESAs — KDIGO 2026
| agent | non-dialysis start | dialysis start |
|---|---|---|
| epoetin alfa/beta | ≈50 U/kg once or twice weekly (or up to 100 U/kg every 2 weeks) | 50–100 U/kg 3× weekly |
| darbepoetin | 0.45 µg/kg weekly or 40–100 µg every 2–4 weeks | 0.45 µg/kg weekly or 0.75 µg/kg every 2 weeks |
| methoxy-PEG epoetin beta | 0.6 µg/kg every 2 weeks or 1.5 µg/kg monthly | 0.6 µg/kg every 2 weeks |
- Start on dialysis when Hb ≤90–100 g/L. Non-dialysis: individualise to symptoms and transfusion risk
- Subcutaneous if not on HD; HD → IV or SC
- Check Hb every 2–4 weeks after a start or dose change. Change the dose no more often than 4-weekly. Hb rise >10 g/L in 2–4 weeks → reduce 25–50% (reduce rather than stop — KDOQI). Maintenance: Hb at least every 3 months
- Dialysis titration: Hb rise <10 g/L at 4 weeks → epoetin +25 U/kg/dose (darbepoetin +25%). Rise >20 g/L → reduce
key points
- Reversible causes first: iron, B12/folate, infection/inflammation, hyperparathyroidism, inadequate dialysis, hypothyroidism, haemolysis, marrow disease
- Lowest dose that meets the goal. Aiming for normal Hb harms: TREAT (2009) (darbepoetin to Hb 130, T2D + CKD) — no CV or kidney benefit, more strokes; CHOIR (2006) (Hb 135 vs 113) — more death/CV events. Practical range ~100–110 g/L (KDOQI)
- Reasonable to suspend during admission for stroke, access thrombosis or VTE; restart individualised. Falling Hb on an ESA → reduce rather than hold
- Transfusion: decide on symptoms, not a Hb number
- Cancer (active or history) → shared decision; aim only to avoid transfusion
- HIF-PHIs (roxadustat, daprodustat, vadadustat…): second line. Meta-analyses show no MACE excess vs ESA, but ESAs have longer safety data (KDOQI). Avoid with cancer, prior MI/stroke/VTE/access thrombosis, ADPKD, proliferative retinopathy, PAH, pregnancy. Never combine with an ESA. Roxadustat: monitor thyroid. Stop if no response by 3–4 months
- Hyporesponsiveness → rework the causes. Consider a HIF-PHI trial. Anti-EPO pure red cell aplasia → stop the ESA and involve haematology
transplant candidates
Avoid transfusion where possible (HLA sensitisation lengthens the wait and harms graft outcomes). Use iron and ESA instead.
evidence
| trial | design | result |
|---|---|---|
| PIVOTAL (2019) | 2141 HD; proactive IV iron sucrose 400 mg/month (hold if ferritin >700 or TSAT ≥40%) vs reactive | MI/stroke/HF admission HR 0.80; less ESA use; no excess infection |
| TREAT (2009) | darbepoetin to Hb 130 vs rescue, T2D + non-dialysis CKD | no benefit on death/CV/kidney outcomes; more stroke |
| CHOIR (2006) | epoetin to Hb 135 vs 113, non-dialysis CKD | more death/CV events in the high-target arm |
adverse effects
- ESA: hypertension, stroke, access thrombosis and VTE (worse at higher Hb), pure red cell aplasia (rare)
- IV iron: infusion reactions mostly minor (Fishbane: flushing, myalgia, chest tightness, no hypotension/wheeze/stridor) → stop, observe, restart at 25–50% rate; no adrenaline or antihistamine. True anaphylaxis (hypotension, wheeze, stridor) → adrenaline 0.5 mg IM, fluids, oxygen, admit, no more IV iron → iron deficiency
- Ferric carboxymaltose: hypophosphataemia (FGF-23-mediated) → osteomalacia with repeated doses
- Oral iron: GI upset, constipation
Prepared 2026-11-01. Not yet verified — check every number against the sources.